Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Integrity Applications — Investor Presentation (November 2017)
22 slides from Glucotrack's investor presentation, Nov 3, 2017
Slide 1: GlucoTrack: A First In Class Non-Invasive Glucose Monitoring Platform
GlucoTrackA First In Class Non-Invasive GlucoseMonitoring Platform Digital Health SolutionSupporting healthy behaviors by providingindividual context to glucose data The Integrity Applications Growth Story Attractive Industry Dynamics Glucose monitoring undergoing rapid disruptive change
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without li
Slide 3: Executive Summary
Unique product , solid clinical dataFirst -in-class non-invasive glucose monitorUnique “triple-sensor” technology combined with proprietary algorithm provides unmatched accuracyApproved for use in T2 and pre-diabetes patients in Europe and AsiaMultiple clinical trials in over 1000 patients Attractiv
Slide 4: Glucose Control is of Interest to a Broad Population Worldwide
Glucose Control is of Interest to a Broad Population Worldwide Health/Wellness1B At Risk250M Pre-Diabetes318M Diabetes (T1/T2)415M Population High performance individualsHealth and WellnessHigh stress professions Obese (BMI > 25kg/m2Genetic risk of diabetesHigh risk pregnancy HbA1C 5.7%-6.4%BMI >25k
Slide 5: Glucose Measurement is Undergoing a Major Transformation
Glucose Measurement is Undergoing a Major Transformation Commercial Monitor only R&D Stage of Development IntegratedSolution Digital HealthProductSolution Google/Novartis GlucoWise (Mediwise) Cnoga Medical Symphony (Echo Tx) Noviosense Medella Health Light Touch Medical GlucoVista Sano GlucoTrack K’
Slide 6: Conventional BGM Fails Due to Two Main Barriers
Conventional BGM Fails Due to Two Main Barriers Finger Pricking Patients dislike the pain on a regular basisExtracting blood can be messyRequires disposablesExpensiveLacks discretion Lack of relevance Does it solve their problems?Does it give them (new) hope?Does it fulfill their needs?Does it bring
Slide 7: GlucoTrack: A Unique Non-Invasive Glucose Monitoring Solution
Eliminates daily finger pricksSimple calibration with ear clip replacement once every six months Cost-effectiveUnlimited testingLess than cost of conventional glucose monitoring Verified algorithm for estimated HBA1CTrend data allows individual monitoring over time GlucoTrackA Unique Non-Invasive Gl
Slide 8: GlucoTrack's Novel Triple-Sensor Technology
Ultrasonic Sound velocity through tissue varies with glucose concentration Electromagnetic Tissue impedance changes with glucose concentration. thermal Heat transfer characteristics of tissue vary with glucose concentration. GlucoTrack’s Novel Triple-Sensor Technology The three independent readings
Slide 9: Accuracy Equivalent to Gold Standard
Accuracy Equivalent to Gold Standard Female: Age: 59; BMI: 29.6; T2DM duration: 1 mo.; No Medications Male; Age: 64; BMI: 22.3; T2DM duration: 24 mos.; Medications: Acrose, Glucophage Sources: Pfutzner Science & Health Institute, Germany and Soroka University Medical Center, Israel, November 2016.
Slide 10: T2 Consensus Error Grid
T2 Consensus Error Grid Zones Number of Points Percentage A+B 304 99.4% A 277 90.2 B 27 9.2 C 1 0.3 D 0 0.0 E 0 0.0 Total 305 100.0 Most Recent Clinical Study Demonstrated 17% MARD and 99.4% of measurements within A+B Zones Type 2 Consensus Error Grid (CEG) Sources: Pfutzner Science & Health Institu
Slide 11: Combining Non-invasive Measurement with Actionable Information
Glucotrack can Combine Non-invasive Measurement with Relevant and Actionable Information. . . …Empowering Patients to Take Control of their Health
Slide 12: Two Strategic Paths, Multi-Billion Global Markets
Two Strategic Paths, Multi-Billion Global Markets Diabetes Regulated Product HealthConsumer Product
Slide 13: Product Strategy
DIGITAL HEALTH SOLUTIONS GlucoTrack app and integration with digital health solutions and health monitoring devices Accuracy & HUMAN FACTORS Reduce calibration, smaller handset, algorithm modifications based on real world use MINIATURIZATION & SCALE Wireless earclip, manufacturing transition to part
Slide 14: Integrity Growth Strategy
Integrity Growth Strategy Digital Health Solutions Create Multiple White Space Opportunities Glucose MonitoringTechnology Platform Glucose MonitoringProduct Solutions Existing Business Adjacent Business White Space Value $ Disease & WellnessManagement 2017 2020 2022+ GlucoTrack Pro Private label/lic
Slide 15: Future GlucoTrack Wireless
FutureGlucoTrack Wireless Wireless ear clip App tailored to maximize healthy patient behaviors
Slide 16: Transforming Integrity
Transforming Integrity Management & Talent Structure & Process Commercial Mindset Product Portfolio Distribution Partners US Focus Integrity in 2016 Where will we be in 2018? Significant Talent GapLack of commercial experience World class managementTrack record in commercialization & diabetes Lack o
Slide 17: Commercialization
Commercialization Commencement of phased product launch in EuropeImproved distributor selectionTransformed sales modelReset pricing and reimbursementBuild patient and HCP advocacyExpand clinical evidenceImplement Digital Health Applications
Slide 18: Proven and Scalable Manufacturing Process
Proven and Scalable Manufacturing Process Contract manufacturing partners:AY Electronics (Israel)A few thousand systems manufactured to dateWistron CorporationTaiwan, Industrial Design & Medical manufacturing arm of Acer ComputersCapable of high volume manufacturingResearch servicesTaiwan FDA (TFDA)
Slide 19: Global Executive Team
Global Executive Team John GrahamCEO and Chairman Senior executive positions at Sanofi Aventis Pharma, Genzyme Corporation, Menarini Group and Ernst & Young; CEO at Invida Pharmaceuticals Sami Sassoun, CPA, USA, BACFO Previously with Bedrock Enterprises, Brean Murray, Cohn Reznick David PodwalskiChi
Slide 20: Advisors and Directors
Advisors and Directors Angela Strand, Vice-ChairmanFounder, senior executive of Nohm; Founder of Strand Strategy; Founder, CEO of Cliffdive Records. Former executive with multiple biotech and digital health companies in diabetes and metabolic disease. Dr. Robert FischellInventor of more than 200 iss
Slide 21: A 21st Century Company for 21st Century Patients
A 21st Century Company for 21st Century Patients Positioned to leverage patients’ increasing willingness to self-manage their healthAbility to have an impact on cost of diabetesInnovative technology enables a new digital health approach to diabetesPotential to improve compliance and play a role in d
Slide 22: Recap of the Story
Recap of the Story Attractive industry dynamicsUnique product with strong clinical dataTransformation underway with near-term tangible resultsCurrently at an inflection point in commercializationUnder-managed and under-invested in the past with upside potentialStrong technology with significant oppo
Integrity Applications — Investor Presentation (November 2017) on 6ix